MSB vs REGN · P/E 29, rev $98.6M vs P/E 14, rev $14.34B
Mesabi Trust (MSB) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Mesabi Trust (MSB) is a steel company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported MSB revenue for 2025-01-31 was $98.6M. Net income was $93.3M. MSB currently screens at market cap $324.3M and trailing P/E 28.7.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
MSB currently screens at market cap $324.3M and trailing P/E 28.7. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the MSB and REGN stock pages for the full models.
Not investment advice.